CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Carotuximab (TRC105)biological
Likely dose
Carotuximab (TRC105) 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01381861
NCT01381861Phase 2Completed
CompareCT.gov

A Phase 2 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Tracon Pharmaceuticals Inc.·interventional·Posted Jun 27, 2011·Updated Mar 5, 2019

In Brief

A Phase 2 clinical trial evaluating Carotuximab (TRC105) for Recurrent Ovarian Cancer and 2 related conditions. Completed, enrolled 23 participants across 7 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 27, 2011
Enrollment StartJul 1, 2011
Primary CompletionAug 1, 2012
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.0 years ago

Interventions

Carotuximab (TRC105)biological

Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle